請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17627完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 曹建和(Jen-Ho Tsao) | |
| dc.contributor.author | Yun-Peng Ma | en |
| dc.contributor.author | 馬雲鵬 | zh_TW |
| dc.date.accessioned | 2021-06-08T00:26:17Z | - |
| dc.date.copyright | 2013-07-19 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-07-15 | |
| dc.identifier.citation | 1. Toronto Lung Transplant Group, Unilateral lung transplantation for pulmonary fibrosis, N Engl J Med 314:1140–1145, 1986.
2. Date H, Trulock EP, Arcidi JM, et al, Improved airway healing after lung transplantation. An analysis of 348 bronchial anastamoises, J Thorac Carciovasc Surg 110:1424–1432, 1995. 3. Orens JB, Estenne M, Arcasoy S, et al, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation, J Heart Lung Transplant 25(7):745–755, 2006. 4. Y.-C. Lee, S.-P. Luh, J.-M. Lee, C.-C. Huang, Y.-L. Chang, H.-D. Wu, S.-H. Kuo, and S.-H. Chu, Lung Transplatation-The NTUH Surgical Experience, Transplantation Proceedings, 30, 3391–3392, 1998. 5. HachemRR,Yusen RD, ChakinalaMM, et al, Randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation, J Heart Lung Transplant 26(10): 1012– 1018, 2007. 6. Celli BR, MacNee W, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J 23:932, 2004. 7. Lin T-J, Lu C-C, Chen K-W, Deng J-M, Outbreak of obstructive impairment associated with consumption of Sauropus androgyrus vegetable, Clin Toxicol 34: 1, 1996. 8. Luh S-P, Lee Y-C, Chang Y-L, Wu H-D, Kuo S-H, Chu S-H, Lung transplantation for patients with end-stage Sauropus androgynus-induced bronchiolitis obliterans (SABO) syndrome, Clin Transplantation13: 497–504, 1999. 9. D’Alonzo GE, Barst RJ, Ayres SM, et al, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med 115:343- 349, 1991. 10. Rich S, Dantzker R, Ayres S, et al, Primary pulmonary hypertension: a national prospective study, Ann Intern Med 107:216–223, 1987. 11. Nootens M, Schrader B, Kaufmann E, et al, Comparative effects of adenosine and prostacyclin in primary pulmonary hypertension, Chest 107:50–53, 1995. 12. Frank H, Mlczoch J, Huber K, et al, The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension, Chest 112:714–721, 1997. 13. Zamora MR, Surgical therapy for chronic obstructive lung disease. Chronic Obstructive Lung Disease 375:395–398, 2008. 14. Badgett RG, Tanaka DJ, Hunt DK, et al, Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med 94:188, 1993. 15. Fishman A, Martinez F, Naunheim K, et al, A randomized trial comparing lung-volume reduction surgery with medical therapy for severe emphysema, N Engl J Med 348:2059, 2003. 16. Hornby K, Ross H, Keshavjee S, et al, Non-utilization of hearts and lungs after consent for donation: a Canadian multicentre study, Can J Anaesth 53(8):831–837, 2006. 17. Ware LB, Wang Y, Fang X, et al, Assessment of lungs rejected for transplantation and implications for donor selection, Lancet 360:619–620, 2002. 18. Venkateswaran RV, Patchell VB, Wilson IC, et al, Early donor management increases the retrieval rate of lungs for transplantation, Ann Thorac Surg 85(1):278–286, 2008. 19. Bittner HB, Kendall SW, Chen EP, et al, The effects of brain death on cardiopulmonary hemodynamics and pulmonary blood flow characteristics, Chest 108(5):1358–1363, 1995. 20. Novitzky D, Wicomb WN, Rose AG, et al, Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon, Ann Thorac Surg 43(3):288–294, 1987. 21. Maron MB, Dawson CA, Pulmonary venoconstriction caused by elevated cerebrospinal fluid pressure in the dog, J Appl Physiol 49(1):73–78, 1980. 22. Fisher AJ, Donnelly SC, Hirani N, et al, Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation, Am J Respir Crit Care Med 163(1):259–26, 2001. 23. McElhinney DB, Khan JH, Babcock WD, et al, Thoracic organ donor characteristics associated with successful lung procurement, Clin Transplant 15(1):68–71, 2001. 24. Rosengard BR, Feng S, Alfrey EJ, et al, Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor, Am J Transplant 2(8):701–711, 2002. 25. Pennefather SH, Bullock RE, Mantle D, et al., Use of low dose arginine vasopressin to support brain-dead organ donors, Transplantation 59(1):58–62, 1995. 26. Kendall SW, Bittner HB, Peterseim DS, et al, Right ventricular function in the donor heart, Eur J Cardiothorac Surg 11(4):609–615, 1997. 27. Rosendale JD, Chabalewski FL, McBride MA, et al., Increased transplanted organs from the use of a standardized donor management protocol, Am J Transplant 2 (8) : 761–768, 2002. 28. Powner DJ, Biebuyck JC, Introduction to the interpretation of chest radiographs during donor care, Prog Transplant 15(3):240–248, 2005. 29. Duggan M, McCaul CL, McNamara PJ, et al, Atelectasis causes vascular leak and lethal right ventricular failure in uninjured rat lungs, Am J Respir Crit Care Med 167(12): 1633–1640, 2003. 30. Mascia L, Bosma K, Pasero D, et al, Ventilatory and hemodynamic management of potential organ donors: an observational survey, Crit Care Med 34(2):321–327, 2006. 31. Steen S, Liao Q, Wierup PN, et al, Transplantation of lungs from non-heart beating donors after functional assessment ex vivo, Ann Thorac Surg 76(1):244–252, 2003. 32. Ingemansson R, Eyjolfsson A, Mared L, et al, Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo, Ann Thorac Surg 87:255–260, 2009. 33. Ries A, Bauldoff G, Carlin B, et al, Pulmonary rehabilitation: joint ACCP/AACVPR evidence- based clinical practice guidelines, Chest 131:4S–42S, 2007. 34. Guell R, Casan P, Belda J, et al, Long-term effects of outpatient rehabilitation of COPD: a randomized trial, Chest 117:976–983, 2000. 35. Raskin J, Spiegler P, McCusker C, et al, The effect of pulmonary rehabilitation on health care utilization in chronic obstructive pulmonary disease: The Northeast Pulmonary Rehabilitation Consortium, J Cardiopulm Rehabil 26:231–236, 2006. 36. Moorcroft A, Dodd M, Morris J, et al, Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial, Thorax 59:1074–1080, 2004. 37. Mereles D, Ehlken N, Kreuscher S, et al, Exercise and respiratory training improve exercisecapacity and quality of life in patients with severe chronic pulmonary hypertension, Circulation 114:1482–148, 2006. 38. Christie JD, Edwards LB, Aurora P, et al, Registry of the international society for heart andlung transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008, J Heart Lung Transplant 27(9):957–969, 2008. 39. DeMeo DL, Ginns LC, Lung transplantation at the turn of the century, Annu Rev Med 52:185–201, 2001. 40. Bavaria JE, Kotloff R, Palevsky H, et al, Bilateral versus single lung transplantation for chronic obstructive pulmonary disease, J Thorac Cardiovasc Surg 113(3):520–527, 1997. 41. Mason DP, Brizzio ME, Alster JM, et al, Lung transplantation for idiopathic pulmonary fibrosis, Ann Thorac Surg 84(4):1121–1128, 2007. 42. Nwakanma LU, Simpkins CE, Williams JA, et al, Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older, J Thorac Cardiovasc Surg 133(2) : 541–547, 2007. 43. Meyers BF, Lynch JP, Trulock EP, et al, Single versus bilateral lung transplantation foridiopathic pulmonary fibrosis: a ten-year institutional experience, J Thorac Cardiovasc Surg 120(1):99–10, 2000. 44. Patterson GA, Todd TR, Cooper JD, et al, Airway complications after double lung transplantation. Toronto Lung Transplant Group, J Thorac Cardiovasc Surg 99:14–20, 1990. 45. Pasque MK, Cooper JD, Kaiser LR, et al, Improved technique for bilateral lung transplantation rationale and initial clinical experience, Ann Thorac Surg 49:785–791, 1990. 46. Lima O, Cooper, JD, Peters WJ, et al, Effects of methylprednisolone and azathioprine on bronchial healing following lung autotransplantation, J Thorac Cardiovasc Surg 82:211–215, 1981. 47. Goldberg M, Lima O, Morgan E, et al, A comparison between cyclosporin A and methylprednisolon plus azathioprine on bronchial healing following canine lung autotransplantation, J Thorac Cardiovasc Surg 85:821–828, 1983. 48. Pettersson G, Norgaard MA, Arendrup H, et al, Direct bronchial artery revasculari- zation and en bloc double lung transplantation—surgical techniques and early outcome, J Heart Lung Transplant 16: 320– 333, 1997. 49. Morgan E, Lima O, Goldberg M, et al, Improved bronchial healing in canine left lung reimplantation using omental pedicle wrap, J Thorac Cardiovasc Surg 85:134–139, 1983. 50. Lau CL, Patterson GA, Palmer SM, Critical care aspects of lung transplantation, J Intensive Care Med 19(2):83–104, 2004. 51. Amato MB, Barbas CS, Medeiros DM, et al, Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome, N Engl J Med 338(6):347–354, 1998. 52. Arcasoy SM, Fisher A, Hachem RR, et al, Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes, J Heart Lung Transplant 24(10):1483-1488, 2005. 53. Christie JD, Kotloff RM, Pochettino A, et al, Clinical risk factors for primary graft failure following lung transplantation, Chest 124:1232–1241, 2003. 54. Christie JD, Sager JS, Kimmel SE, et al, Impact of primary graft failure on outcomes following lung transplantation, Chest 127:161–165, 2005. 55. Daud SA, Yusen RD, Meyers BF, et al, Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome, Am J Respir Crit Care Med 175:507-513, 2007. 56. Shargall Y, Guenther G, Ahya VN, et al, Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment, J Heart Lung Transplant 24:1489–1500, 2005. 57. Adatia I, Lillehei C, Arnold JH, et al, Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation, Ann Thorac Surg 57:1311–1318, 1994. 58. Meyers BF, Sundt TM 3rd, Henry S, et al, Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation, J Thorac Cardiovasc Surg 120:20–26, 2000. 59. Smedira NG, Moazami N, Golding CM, et al, Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years, J Thorac Cardiovasc Surg 122:92–102, 2001. 60. Clark SC, Levine AJ, Hasan A, et al, Vascular complications of lung transplantation, Ann Thorac Surg 61(4):1079–1082, 1996. 61. Liguori C, Schulman LL, Weslow RG, et al, Late pulmonary venous complications after lung transplantation, J Am Soc Echocardiogr 10(7):763–767, 1997. 62. Berger H, Steiner W, Stabler A, et al, Radiologic interventions in anastomosis complications after lung transplantation, Radiologe 37(3):220–224, 1997. 63. Rhen T, Cidlowski JA., Antiinflammatory action of glucocorticoids—new mechanisms for old drugs, N Engl J Med 2005; 353(16):1711–1723, 2005. 64. Barnes PJ. How corticosteroids control inflammation, Br J Pharmacol 148(3):245–254, 2006. 65. Christie JD, Edwards LB, Aurora P, et al, Registry of the international society for heart andlung transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008, J Heart Lung Transplant 27(9):957–969, 2008. 66. Azzola A, Havryk A, Chhajed P, et al, Everolimus and Mycophenolate Mofetil are potet inhibitors of fibroblast proliferation after lung transplantation, Transplantation 77(2): 275–280, 2004. 67. Tamm M, Aboyoun CL, Chhajed PN, et al, Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome, Am J Respir Crit Care Med 170 :1120–1123. 2004. 68. Danziger-Isakov LA, Delamorena M, Hayashi RJ, et al, Cytomegalovirus viremia associatedwith death or retransplantation in pediatric lung transplant recipients, Transplantation 75(9):1538–154, 2003. 69. Kotsimbos AT, Sinickas V, Glare EM, et al, Quantitative detection of human cyto- megalovirus DNA in lung transplant recipients, Am J Respir Crit Care Med 156(4): 1241–1246, 1997. 70. Alexander BD, Tapson VF, Infectious complications of lung transplantation. Transpl Infect Dis, 3(3):128–137, 2001. 71. Aguilar-Guisado M, Givalda J, Ussetti P, et al, Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study , Am J Transplant 7(8):1989– 1996, 2001. 72. Valentine VG, Bonvillain RW, Gupta MR, et al, Infections in lung allograft recipients: ganciclovir era, J Heart Lung Transplant 27(5):528–535, 2008. 73. Paterson DL, Singh N, Rihs JD, et al, Control of an outbreak of infection due to extended spectrum beta-lactamase—producing Escherichia coli in a lung transplantation unit, Clin Infect Dis 33(1):126– 128, 2001. 74. Kawut SM, Lederer DJ, Keshavjee S, et al, Outcomes after lung retransplantation in the modern era, Am J Respir Crit Care Med 177(1):114–120, 2008. 75. Aigner C, Jaksch P, Taghavi S, et al, Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases, J Heart Lung Transplant 27(1):60–65, 2008. 76. Hill JD, O’Brien TG, Murrary JJ, et al, Prolonged extracorporeal oxygenation for acute post- traumatic respiratory failure - Use of the Bramson artificial lung, N Engl J Med 286:629–634, 1976. 77. Zapol WM, Snider MT, Hill JD, et al, Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study, JAMA 242:2193–2196,1979. 78. Peek G, Mugford M, Tiruvoipati R, et al, Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure : a multicentre randomized controlled trial, Lancet 374:1351–1366, 2009. 79. Lynch JE, Zwischenberger JB, Will CESAR answer the adult ECMO debate? Lancet 374 (9698) :1307–1308, 2009. 80. Zwischenberger JB, Anderson CM, Cook KE, et al, Development of an implantable artificial lung: challenges and progress, ASAIO J 47(4):316–320, 2001. 81. Zwischenberger JB, Wang D, Lick SD, et al, The paracorporeal artificial lung improves 5-day outcomes from lethal smoke/burn-induced acute respiratory distress syndrome in sheep, Ann Thorac Surg 74:1011–1018, 2002. 82. Lillehei CW, DeWall RA, Read RC, et al, Direct vision intracardiac surgery in man using a simple disposable artificial oxygenator, Dis Chest 1956; 29:1–8, 1956. 83. Kolff WJ, Balzer RR, Artficiial coil lung, Trans Am Soc Artif Intern Organs 1:23,1955. 84. Kolobow T., The artificial lung: the past. A personal perspective, ASAIO J 50(6):xliii– xlviii, 2004. 85. Clowes GHA, Hopkins AL, Kolobow T, Oxygen diffusion through plastic films, Trans Am Soc Artif Intern Organs 1:2, 1955. 86. Khoshbin E, Roberts N, Harvey C, et al, Poly-methyl pentene oxygenators have improvedgas exchange capability and reduced transfusion requirements in adult extracorporeal membrane oxygenation, ASAIO J 51:281–287, 2005. 87. Lawson D, Richard I, Cheifetz I, et al, Hemolytic characteristics of three commercially available centrifugal blood pumps, Pediatr Crit Care Med 6:573–577, 2005. 88. Hartwig MG, Appel JZ, Cantu E, et al, Improved results treating lung allograft failure with venovenous extracorporealmembrane oxygenation, Ann Thorac Surg 80:1872– 1880, 2005. 89. Bittner HB, Binner C, Lehmann S, et al, Replacing cardiopulmonary bypass with extracorporeal membrane oxygenation in lung transplantation operations, Eur J Cardiothorac Surg 31(3):462–467, 2007. 90. Zwischenberger JB, Cox CS Jr, A new intravascular membrane oxygenator to augment blood gas transfer in patients with acute respiratory failure, Tex Med 87:60–63, 1991. 91. Cox CS Jr, Zwischenberger JB, Graves DF, et al, Intracorporeal CO2 removal and permissive hypercapnia to reduce airway pressure in acute respiratory failure. The theoretical basis for permissive hypercapnia with IVOX, ASAIO J 39(2):97–102, 1993. 92. Matheis G, New technologies for respiratory assist, Perfusion 18:171–177, 2003. 93. Hattler BG, Lund LW, Golob J, et al, A respiratory gas exchange catheter: in vitro and in vivo tests in large animals, J Thorac Cardiovasc Surg 124(3):520–533, 2002. 94. Chen H, Shiboski S, Golden J, et al, Impact of the lung allocation score on lung transplantation or pulmonary arterial hypertension, Am J Respir Crit Care Med 180: 468–474, 2009. 95. Boschetti F, Perlman CE, Cook KE, et al, Hemodynamic effects of attachment modes and device design of a thoracic artificial lung, ASAIO J 46:42–48, 2000. 96. Lick SD, Zwischenberger JB, Wang D, et al., Improved right heart function with a compliant inflow artificial lung in series with the pulmonary circulation, Ann Thorac Surg 72(3):899–904, 2001. 97. Zhang J, Taskin ME, Koert A, et al, Computational design and in vitro characterization of an integrated Maglev pump oxygenator, Artif Organs 33(10):805–817, 2009. 98. Wang D, Zhou X, Liu X, et al, Wang-Zwische Double lumen-cannula—toward a per- cutaneous and ambulatory paracorporeal artificial lung, ASAIO J 54(6):606–611, 2008. 99. Bjortuft O, Foerster A, Boe J, Geiran O. Single lung transplantation as treatment for end-stage pulmonary sarcoidosis: recurrence of sarcoidosis in two different lung allografts in one patient, J Heart Lung Transplant 13: 24, 1994. 100. Nine JS, Yousem SA, Paradis IL, Keenanr R, Griffith BP, Lymphangio leiomyomatosis: recurrence after lung transplantation, J Heart Lung Transplant 13: 714, 1994. 101. Chang Y-L, Yao Y-T, Wang N-S, Lee Y-C. Segmental necrosis of small bronchi after prolonged intakes of Sauropus androgynus in Taiwan, Am J Respir Crit Care Med 157: 594, 1998. 102. Lai R-S, Chiang A-A, Wu M-T, Wang J-S, Lai N-S, Lu J-Y, Ger L-P, Roggli V, Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan, Lancet 348: 83, 1996. 103. Sakakibara H, Taki K, Kawanishi M, Shimaday Y, Ishikawawa N, Lung vascular permeability enhanced by sympathetic nerve stimulation in rats, Japan J Pharmacol 56: 391, 1991. 104. Davila JC, Davis PJ, Acosta D, Changes in glutathione and cellular energy as potential mechanisms of papaverineinduced hepatotoxicity in vitro, Toxicol Appl Pharmacol 108: 28, 1991. 105. Chen C-W, Hsiue T-R, Chen K-W, Chang H-Y, Chen C-R, Yang B-C. Increased IL-5 and IL-10 transcription in bronchial cells after Sauropus androgynus ingestion, J Formos Med Assoc 95: 699, 1996. 106. Cohen RG, Barr ML, Starnes VA, et al, Living related donor lobectomy for bilateral lobar transplantation in patients with pulmonary fibrosis, Ann Thorac Surg 57: 1423-1428, 1994. 107. Ulicny KS, Egan TM, Lambert CJ, et al, Cadavor lung donors: Effect of pro- harvest ventilation of graft function, Ann Thorac Surg 55:1185-1191, 1993. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17627 | - |
| dc.description.abstract | 肺臟置換療法是解決末期肺臟功能障礙的根本方法，肺臟置換療法包括肺臟移植以及人工肺臟，肺臟移植是目前肺臟置換療法中較為可行的方法，但是肺臟移植受限於肺臟捐贈的短缺，長期性人工肺臟在未來的實際使用，將是根本的解決辦法。在本論文中，根據台大醫院的十二例肺臟移植經驗，藉以了解肺臟置換療法的要點，並且檢視台大醫院肺臟置換療法的有效性，進而對未來長期性人工肺臟的實際運作與執行做可行性評估。
台大醫院的肺臟置換療法，其適應症包括有慢性阻塞性肺病，原發性肺動脈高壓和守宮木所致的閉鎖性細支氣管炎。從肺臟移植的實際案例經驗予以探索反證，冀望能由了解台大醫院肺臟移植案例成功的關鍵因素，包括術後的感染控制、排斥反應的免疫抑制、以及血管接合術的技能改進等等，將有助於人工肺臟的成功表現。 人工肺臟的氣體交換發生於人造通透膜處，這人造通透膜也是體外肺膜氧合器（葉克膜）的前身。葉克膜和血管內氧合器只容許數天到數週的使用時間，但是隨身型人工肺臟能提供比葉克膜或血管內氧合器更長的使用時間。隨身型人工肺臟的結構類型包括有肺動脈至左心房型，肺動脈至肺動脈型，右心房至肺動脈型，以及雙腔靜脈幫浦型。 長期性人工肺臟的需求背景來自葉克膜受限於較短的使用時間，而其技術需求則主要是在於克服葉克膜的人造通透膜的生物相容性問題，這技術需求也因此導致了幹細胞的引進應用。由於對自身肺臟幹細胞無排斥反應的特性，使得以肺臟幹細胞覆蓋於具生物相容性的人工肺臟支架時，將表現出完全相容的長期性人工肺臟。這種生物醫學科技將結合肺臟移植的手術技能和幹細胞的增殖技術與生物相容性人工肺臟支架，如此以肺臟幹細胞再生技術做為人工肺臟的肺臟置換療法，將是未來完美的長期性人工肺臟。 | zh_TW |
| dc.description.abstract | Lung replacement therapy is the radical way to solve the problem of the end-stage pulmonary dysfunction. The lung replacement therapy includes both lung transplantation and artificial lung, the lung transplantation is the feasible method of the lung replacement therapy nowadays, but this operation is limited to the shortage of the donor lungs. The future practical use of the long-term artificial lung will be the radical solution. According to the 12 cases of lung transplantation reported by NTUH (National Taiwan University Hospital) and checking the effectiveness of the lung replacement therapy in NTUH, it is contributive to perform the artificial lung by virtue of the understanding and mature practice of the lung transplantation.
The indications for lung replacement therapy in NTUH include chronic obstructive pulmonary disease, primary pulmonary hypertension and Sauropus Androgynus-induced bronchiolitis obliterans. To understand the successful key factors of the lung transplantation in NTUH, e.g. control of the infection, immunosuppression for the rejection, and the skill of the vascular anastomosis, is helpful to the successful performance of the artificial lung. The gas exchange of the artificial lung could occur across a man-made membrane. The spiral coiled membrabe lung is the forerunner of the ECMO (extracorporeal membrane oxygenation). ECMO and intravascular oxygenator allow only for days to weeks, but paracorporeal artificial lung provides the longer duration than ECMO or intravascular oxygenator. The configurations of the paracorporeal artificial lung include pulmonary artery to left atrium, pulmonary artery to pulmonary artery, right atrium to pulmonary artery, and the double lumen venovenous configuration with a pump. The task requirement for long-term artificial lung is based on the limitation of the shorter utility of ECMO and the technique requirement for long-term artificial lung is mainly to overcome the problem of the biocompatibility of the man-made membrane of ECMO. Therefore, it causes the application of stem cells. The character of the stem cells will be totally compatible with the artificial lung while the artificial lung is treated with the pulmonary stem cells covered the biocompatible scaffold. This biomedical technology will combine the surgical skill of the lung transplantation and biotechnique of the proliferation of the stem cells of the recipient with the biocompatible scaffold to regenerate the artificial lung. The perfect solution of the long-term lung replacement therapy will be the stem-cell regeneration of the artifiial lung. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T00:26:17Z (GMT). No. of bitstreams: 1 ntu-102-R96945016-1.pdf: 1832409 bytes, checksum: 478bd4d05332e632a120c1b945239485 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | Chapter 1 Introduction……………………………1
1.1 Motive and methodology………………………1 1.2 History of lung replacement therapy……2 1.3 Patient selection and support for lung replacement therapy...3 Chapter 2 Existing method of lung replacement therapy...6 2.1 Indications for lung replacement therapy in NTUH....6 2.2 Lung transplantation……………14 Chapter 3 Artificial lung……………………24 3.1 Development of artificial lung...24 3.2 Task analysis for long-term artificial lung…………………………………33 3.3 Technical requirements for long-term artificial lung…………………………36 Chapter 4 Results and conclusion…………………40 References……………………………46 | |
| dc.language.iso | en | |
| dc.title | 台大醫院的肺臟置換療法 | zh_TW |
| dc.title | Lung Replacement Therapy in National Taiwan University Hospital | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 江啟輝(Chi-Huei Chiang),黃炳勳(Biing-Shiun Huang) | |
| dc.subject.keyword | 肺臟置換療法,人工肺臟,慢性阻塞性肺病,原發性肺動脈高壓,閉鎖性細支氣管炎, | zh_TW |
| dc.subject.keyword | lung replacemet thnerapy,artificial lung,chronic obstructive pulmonary disease,primary pulmonary hypertension,bronchiolitis obliterans, | en |
| dc.relation.page | 59 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2013-07-15 | |
| dc.contributor.author-college | 電機資訊學院 | zh_TW |
| dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
| 顯示於系所單位： | 生醫電子與資訊學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 目前未授權公開取用 | 1.79 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。